European Journal of Cancer
Volume 39, Issue 9 , Pages 1228-1233 , June 2003

Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

  • L. Mauriac

      Affiliations

    • Institut Bergonié, Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, 229, cours de l'Argonne, 33076 Bordeaux, France
    • Corresponding Author InformationCorresponding author. Tel.: +33-5-5633-3333; fax: +33-5-5633-3385
    • ,
  • J.E. Pippen

      Affiliations

    • Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA
    • ,
  • J. Quaresma Albano

      Affiliations

    • Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal
    • ,
  • S.Z. Gertler

      Affiliations

    • Ottawa Regional Cancer Center, Ottawa, ON, Canada
    • ,
  • C.K. Osborne

      Affiliations

    • Breast Center at Baylor College of Medicine and Methodist Hospital, Houston, TX, USA

Received 6 September 2002 ,Revised 2 January 2003 ,Accepted 26 February 2003.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0959-8049(03)00199-0

doi: 10.1016/S0959-8049(03)00199-0

European Journal of Cancer
Volume 39, Issue 9 , Pages 1228-1233 , June 2003

Article Tools

* Image Usage & Resolution